Search results for "Cardiovascular diseases"

showing 10 items of 2174 documents

A low threshold to ECG-gated repeat CTA reduces the risk of false-positive diagnosis of type A dissection in interhospital referrals: a case series s…

2018

Angela Kornberger,1 Iris Burck,2 Hazem El Beyrouti,1 Nancy Halloum,1 Andres Beiras-Fernandez,1 Christian-Friedrich Vahl1 1Department of Cardiothoracic and Vascular Surgery, University Hospital of Johannes Gutenberg University, Mainz, Germany; 2Department of Diagnostic and Interventional Radiology, University Hospital of Johann Wolfgang Goethe University, Frankfurt am Main, Germany Background: False-positive diagnosis of acute Stanford type A aortic dissection (AAD) on computed tomography angiography (CTA) is still an issue and may lead to substantial consequences. Given that electrocardiography (ECG)-gated CTA provides greater diagnostic safety, it may be assumed that interhospital referral…

medicine.medical_specialtyStanford type A dissectionTherapeutics and Clinical Risk Managementfalse-positive diagnosisECG-gated CTA030204 cardiovascular system & hematology030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinemedicinePharmacology (medical)Case Seriescardiovascular diseasesGeneral Pharmacology Toxicology and PharmaceuticsType a dissectionComputed tomography angiographyAortic dissectionChemical Health and Safetymedicine.diagnostic_testbusiness.industrymusculoskeletal neural and ocular physiologyGeneral Medicinemedicine.diseaseRadiologybusinessSafety ResearchElectrocardiographypsychological phenomena and processesCase seriesTherapeutics and Clinical Risk Management
researchProduct

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart diseas…

2013

AIMS: The first aim was to critically evaluate the extent to which familial hypercholesterolaemia (FH) is underdiagnosed and undertreated. The second aim was to provide guidance for screening and treatment of FH, in order to prevent coronary heart disease (CHD).METHODS AND RESULTS: Of the theoretical estimated prevalence of 1/500 for heterozygous FH, <1% are diagnosed in most countries. Recently, direct screening in a Northern European general population diagnosed approximately 1/200 with heterozygous FH. All reported studies document failure to achieve recommended LDL cholesterol targets in a large proportion of individuals with FH, and up to 13-fold increased risk of CHD. Based on prev…

medicine.medical_specialtyStatinAtherosclerosis; Cardiovascular disease; Cholesterol; Coronary heart disease; Low-density lipoproteinSettore MED/09 - Medicina Internamedicine.drug_classPopulationCHILDRENFamilial hypercholesterolemiaBile acid bindingCOST-EFFECTIVENESS ANALYSIS030204 cardiovascular system & hematologyLDL-CHOLESTEROLDIAGNOSIS03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeInternal medicineDiabetes mellitusmedicineMANAGEMENT030212 general & internal medicineeducationHealth aging / healthy living Cardiovascular diseases [IGMD 5]Alirocumabeducation.field_of_studyCYTOKINE PATTERN CHANGEbusiness.industryLow-density lipoproteinmedicine.diseaseAtherosclerosisCardiovascular diseaseLomitapideDENSITY-LIPOPROTEIN APHERESIS3. Good healthASSOCIATION EXPERT PANELCoronary heart diseaseEndocrinologyCholesterolchemistryCARDIOVASCULAR-DISEASEAtherosclerosiCardiology and Cardiovascular MedicinebusinessSTATIN TREATMENTmedicine.drugEuropean Heart Journal
researchProduct

Clinical review: impact of statin substitution policies on patient outcomes.

2009

Background. The increasing awareness of cost issues in health care has led to the increasing use of policy-driven substitution of branded for generic medications, particularly relative to statin treatment for cardiovascular diseases. While there are potential short-term health care savings, the consequences for primary care are under-researched. Our objective was to review data on intensive statin therapy and generic substitution in patients at high cardiovascular risk. Results. Current treatment guidelines for the prevention of cardiovascular disease are consistent in their recommendations regarding statin therapy and treatment targets. Clinical trials demonstrate that to reduce cardiovasc…

medicine.medical_specialtyStatinCost effectivenessmedicine.drug_classDiseasePlaceboReimbursement MechanismsRisk FactorsHealth caremedicineDrugs GenericHumanscardiovascular diseasesIntensive care medicinebusiness.industryPublic healthHealth Policynutritional and metabolic diseasesGeneral MedicineClinical trialEuropeCardiovascular DiseasesPractice Guidelines as TopicPhysical therapyObservational studylipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorsbusiness
researchProduct

Statin intolerance: new data and further options for treatment

2021

Purpose of review Hypercholesterolemia is a major risk factor for cardiovascular diseases. Administration of statins represents the cornerstone of the prevention and treatment of cardiovascular disease, with demonstrated long-term safety and efficacy. This review aims to revisit statin intolerance mechanisms, as well as to discuss new data and therapeutic options. Recent findings Although statins are well tolerated, myopathy and other adverse effects are a challenging problem, being the main reason for poor adherence to treatment and failure in lowering cardiovascular risk. Statin intolerance is the subject of ongoing research, as these drugs are widely used. There are alternative options o…

medicine.medical_specialtyStatinDosemedicine.drug_classHypercholesterolemiaDisease030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeHumansMedicinecardiovascular diseases030212 general & internal medicineRisk factorIntensive care medicineAdverse effectbusiness.industryCholesterolAnticholesteremic Agentsangiopoietin-like 3 protein inhibitors bempedoic acid ezetimibe proprotein convertase subtilisin-kexin type 9 inhibitors statin intolerance Cholesterol LDL Ezetimibe Humans Proprotein Convertase 9 Anticholesteremic Agents Cardiovascular Diseases Hydroxymethylglutaryl-CoA Reductase Inhibitors Hypercholesterolemianutritional and metabolic diseasesCholesterol LDLEzetimibeRegimenchemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9Cardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct

An Update on the Role of the Quality of LDL in Cardiovascular Risk:The Contribution of the Universities of Palermo and Zurich

2007

Low density lipoproteins (LDL) size seems to be an important predictor of cardiovascular events and progression of coronary artery disease and the predominance of small dense LDL have been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. We recently showed increased LDL size or higher levels of small, dense LDL in different categories of patients at higher cardiovascular risk, such as those with coronary (including acute myocardial infarction) and non-coronary (including carotid disease, abdominal aortic aneurysm and peripheral arterial disease) forms of atherosclerosis or metabolic diseases (including type-II diabet…

medicine.medical_specialtyStatinUniversitiesmedicine.drug_classCoronary artery diseaseEzetimibeInternal medicineDrug DiscoverymedicineHumansPharmacology (medical)RosuvastatinCholesterol absorption inhibitorParticle SizeRisk factorNational Cholesterol Education Programbusiness.industrymedicine.diseasePolycystic ovaryLipoproteins LDLItalyCardiovascular DiseasesCardiologylipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessSwitzerlandmedicine.drugRecent Patents on Cardiovascular Drug Discovery
researchProduct

Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

2015

Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10-15% of patients. In clinical practice, statin intolerance limits effective…

medicine.medical_specialtyStatinbusiness.industrymedicine.drug_classAlternative medicinePlacebo-controlled studynutritional and metabolic diseasesGeneral MedicineDiseasecomputer.software_genre3. Good healthlaw.inventionRandomized controlled triallawPost-hoc analysismedicinePosition paperlipids (amino acids peptides and proteins)cardiovascular diseasesData miningbusinessIntensive care medicineAdverse effectcomputerArchives of Medical Science
researchProduct

Rational for statin use in psoriatic patients

2013

Psoriasis represents a common skin disease which is clinically manifested by chronic cutaneous lesions. It has been observed that psoriasis is associated with an increased risk of cardiovascular diseases, which is contributed to the inappropriate lipid metabolism. Statins are commonly used in clinical practice to lower cholesterol concentration and, accordingly, decrease the individual risk of developing a cardiovascular episode. There have been reports that statin administration could also result in better management of psoriasis. The observed beneficial effects are contributed to the effects on lipid metabolism, including that in skin, as well as anti-inflammatory and immunomodulatory pro…

medicine.medical_specialtyStatinmedicine.drug_classAtorvastatinDermatologyDiseasePharmacologychemistry.chemical_compoundPsoriasisInternal medicinemedicineAnimalsHumansPsoriasiscardiovascular diseasesSkinCholesterolbusiness.industrynutritional and metabolic diseasesPsoriasis Statins Cholesterol Atorvastatin Fluvastatin SimvastatinGeneral Medicinemedicine.diseaseTreatment OutcomechemistrySimvastatinlipids (amino acids peptides and proteins)Dermatologic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPravastatinmedicine.drugFluvastatin
researchProduct

High-Sensitivity C-Reactive Protein and Statin Initiation

2014

The assessment of cardiovascular risk and treatment of cardiovascular diseases are major public health issues worldwide. Inflammation is now recognized as a key regulatory process that links multiple risk factors for atherosclerosis. The substantial number of patients having cardiovascular events lack commonly established risk factors. The utility of high-sensitivity C-reactive protein (hsCRP), a circulating biomarker related to inflammation, may provide additional information in risk prediction. This review will consider the impact of hsCRP level on initiation of statin therapy.

medicine.medical_specialtyStatinmedicine.drug_classInflammationBioinformaticsMultiple risk factorsRisk AssessmentPredictive Value of TestsRisk FactorsmedicineHumanscardiovascular diseasesDyslipidemiasInflammationbiologybusiness.industryPublic healthC-reactive protein3. Good healthCirculating biomarkersC-Reactive ProteinTreatment OutcomeCardiovascular DiseasesPractice Guidelines as TopicPhysical therapybiology.proteinBiomarker (medicine)Statin therapyHydroxymethylglutaryl-CoA Reductase InhibitorsInflammation Mediatorsmedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersAngiology
researchProduct

A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations.

2015

AbstractThe impact of statin therapy on plasma asymmetric dimethylarginine (ADMA) levels has not been conclusively studied. Therefore the aim of the meta-analysis was to assess the effect of statins on circulating ADMA levels. We searched selected databases (up to August 2014) to identify randomized controlled trials (RCTs) that investigate the effect of statins on plasma ADMA concentrations. A weighted meta-regression (WMD) using unrestricted maximum likelihood model was performed to assess the impact of statin dose, duration of statin therapy and baseline ADMA concentrations as potential variables on the WMD between statin and placebo group. In total, 1134 participants in 9 selected RCTs …

medicine.medical_specialtyStatinmedicine.drug_classUrologyPlaceboArgininePlacebo groupArticlelaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicineMedicineHumanscardiovascular diseasesRandomized Controlled Trials as TopicMultidisciplinarybusiness.industrynutritional and metabolic diseasesPublication biasConfidence intervalEndocrinologychemistryMeta-analysisEndothelium VascularHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessAsymmetric dimethylargininePublication BiasScientific reports
researchProduct

Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

2015

Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term ‘statin intolerance’. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10 – 15% of patients.In clinical practice, statin intolerance limits effectiv…

medicine.medical_specialtyStatinmedicine.drug_classbusiness.industrynutritional and metabolic diseasesGeneral MedicineDisease3. Good healthClinical PracticemedicineEuropean atherosclerosis societyPhysical therapyEffective treatmentPosition paperlipids (amino acids peptides and proteins)Pharmacology (medical)cardiovascular diseasesStatin therapyIntensive care medicinebusinessAdverse effectExpert Opinion on Drug Safety
researchProduct